4D Molecular Q3 revenue $0.5M, net loss $25.7M; cash $239M covers into H1 2025; 4D-710 CF data positive

4D Molecular Therapeutics, Inc.

2022-Q3 EPS reported -$2.48 revenue$1,882,000

Cash, cash equivalents and marketable securities totaled $239M; runway into first half of 2025.
Revenue $0.5M (down from $1.4M), net loss $25.7M vs $22.2M, R&D $18.9M.
Interim Phase 1/2 data for 4D-710 CF: no drug-related adverse events, widespread transgene expression in all lung samples.
Clinical progress highlighted across 4D-150, 4D-310, and 4D-710 programs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

4D Molecular Therapeutics, Inc. reported the quarter ended September 30, 2022 results: revenue $0.5 million, net income $25.7 million.

Period: the quarter ended September 30, 2022
Revenue: $0.5 million
Net income: $25.7 million
Result: reported results

Exact text from the filing

Revenue: Total revenue for the quarter ended September 30, 2022, was $0.5 million, as compared to $1.4 million for the quarter ended September 30, 2021.

View on SEC.gov

Browse all earnings releases →

4D Molecular Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023839

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.